Literature DB >> 19337217

Left ventricular hypertrophy in renal disease: beyond preload and afterload.

Eberhard Ritz.   

Abstract

To explain ventricular concentric and/or eccentric hypertrophy in chronic kidney disease, past studies suggested that this was the result of increased preload and/or afterload. Using a renal ablation model of the mouse with documented absence of hypertension, Siedlecki et al. provide evidence for the involvement of the mammalian target of rapamycin (mTOR) pathway. This suggests that load-independent primary stimuli trigger or contribute to ventricular hypertrophy and fibrosis in uremia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19337217     DOI: 10.1038/ki.2009.35

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  26 in total

Review 1.  Diagnosis and Management of Heart Failure in Long-Term Dialysis Patients.

Authors:  Ashraf S Abdo
Journal:  Curr Heart Fail Rep       Date:  2017-10

Review 2.  Sodium potassium adenosine triphosphatase (Na/K-ATPase) as a therapeutic target for uremic cardiomyopathy.

Authors:  Xiaoliang Wang; Jiang Liu; Christopher A Drummond; Joseph I Shapiro
Journal:  Expert Opin Ther Targets       Date:  2017-04-03       Impact factor: 6.902

3.  Renal dysfunction and diastolic impairment among British ethnic minorities with hypertension: the Ethnic-Echocardiographic Heart of England Screening Study.

Authors:  A Shantsila; E Shantsila; P S Gill; G Y H Lip
Journal:  J Hum Hypertens       Date:  2016-09-08       Impact factor: 3.012

4.  Long-term effects of spironolactone in peritoneal dialysis patients.

Authors:  Yasuhiko Ito; Masashi Mizuno; Yasuhiro Suzuki; Hirofumi Tamai; Takeyuki Hiramatsu; Hiroshige Ohashi; Isao Ito; Hirotake Kasuga; Masanobu Horie; Shoichi Maruyama; Yukio Yuzawa; Tatsuaki Matsubara; Seiichi Matsuo
Journal:  J Am Soc Nephrol       Date:  2013-12-12       Impact factor: 10.121

5.  The relationship between R wave peak time and left ventricular mass index in patients with end-stage renal disease on hemodialysis.

Authors:  Macit Kalçık; Mucahit Yetim; Tolga Doğan; Barış Eser; İbrahim Doğan; Lütfü Bekar; Oğuzhan Çelik; Yusuf Karavelioğlu
Journal:  Int Urol Nephrol       Date:  2019-09-30       Impact factor: 2.370

6.  Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease.

Authors:  Robert N Foley; Bryan M Curtis; Edward W Randell; Patrick S Parfrey
Journal:  Clin J Am Soc Nephrol       Date:  2010-04-08       Impact factor: 8.237

Review 7.  Cardiac actions of fibroblast growth factor 23.

Authors:  Christian Faul
Journal:  Bone       Date:  2016-10-07       Impact factor: 4.398

8.  Cardiac and renal function are progressively impaired with aging in Zucker diabetic fatty type II diabetic rats.

Authors:  John Baynes; David B Murray
Journal:  Oxid Med Cell Longev       Date:  2009 Nov-Dec       Impact factor: 6.543

Review 9.  Left Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment.

Authors:  Luca Di Lullo; Antonio Gorini; Domenico Russo; Alberto Santoboni; Claudio Ronco
Journal:  Cardiorenal Med       Date:  2015-07-15       Impact factor: 2.041

Review 10.  Pediatric cardiomyopathies: causes, epidemiology, clinical course, preventive strategies and therapies.

Authors:  Steven E Lipshultz; Thomas R Cochran; David A Briston; Stefanie R Brown; Peter J Sambatakos; Tracie L Miller; Adriana A Carrillo; Liat Corcia; Janine E Sanchez; Melissa B Diamond; Michael Freundlich; Danielle Harake; Tamara Gayle; William G Harmon; Paolo G Rusconi; Satinder K Sandhu; James D Wilkinson
Journal:  Future Cardiol       Date:  2013-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.